 Interleukin-17
"Interleukin-17" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proinflammatory cytokine produced primarily by T-LYMPHOCYTES or their precursors. Several subtypes of interleukin-17 have been identified, each of which is a product of a unique gene.
| Descriptor ID |
D020381
|
| MeSH Number(s) |
D12.644.276.374.465.517 D12.776.467.374.465.517 D23.529.374.465.517
|
| Concept/Terms |
Interleukin-17F- Interleukin-17F
- Interleukin 17F
- IL-17F
- Cytokine ML-1
- Cytokine ML 1
Interleukin-17D- Interleukin-17D
- Interleukin 17D
- IL-17D
- Interleukin-27
- Interleukin 27
Interleukin-17E- Interleukin-17E
- Interleukin 17E
- Interleukin-25
- Interleukin 25
- IL-17E
- IL 17E
Interleukin-17A- Interleukin-17A
- Interleukin 17A
- Cytotoxic T lymphocyte-Associated Antigen 8
- Cytotoxic T lymphocyte Associated Antigen 8
- IL-17A
- CTLA8
Interleukin-17C- Interleukin-17C
- Interleukin 17C
- IL-17C
- Cytokine CX2
- CX2, Cytokine
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-17".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-17".
This graph shows the total number of publications written about "Interleukin-17" by people in this website by year, and whether "Interleukin-17" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 5 | 3 | 8 | | 2010 | 2 | 2 | 4 | | 2011 | 3 | 4 | 7 | | 2012 | 1 | 2 | 3 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 1 | 5 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 3 | 4 | | 2017 | 1 | 1 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 5 | 2 | 7 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-17" by people in Profiles.
-
Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D'Adamio S, Magnano M, Bernardini N, Malagoli P, Bardazzi F, Potenza C, Bianchi L, Peris K, De Simone C. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020 06; 20(6):665-672.
-
Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
-
Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
-
Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, Chen YE, Li K, Farhat S, Weckel A, Krishnamurthy SR, Vujkovic-Cvijin I, Linehan JL, Bouladoux N, Merrill ED, Roy S, Cua DJ, Adams EJ, Bhandoola A, Scharschmidt TC, Aubé J, Fischbach MA, Belkaid Y. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science. 2019 10 25; 366(6464).
-
van Vugt LJ, van den Reek JMPA, Meulewaeter E, Hakobjan M, Heddes N, Traks T, Kingo K, Galluzzo M, Talamonti M, Lambert J, Coenen MJH, de Jong EMGJ. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
-
Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 08; 50(4):373-385.
-
Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 12; 139(12):2437-2446.e1.
-
Galluzzo M, D'Adamio S, Teoli M, Bianchi L, Talamonti M. Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019 05; 32(3):e12899.
-
Huang LH, Zinselmeyer BH, Chang CH, Saunders BT, Elvington A, Baba O, Broekelmann TJ, Qi L, Rueve JS, Swartz MA, Kim BS, Mecham RP, Wiig H, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. Cell Metab. 2019 02 05; 29(2):475-487.e7.
-
Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|